A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models

Medical Physics

Volumn 37, Issue 5, 2010, Pages 1987-1994

  Bednarz, Bryan ^a,b   Athar, Basit ^a,b   Xu, X George ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Monte Carlo; Out of field dose; Second cancer

Indexed keywords

DISEASES; MONTE CARLO METHODS; RADIOTHERAPY; UROLOGY;

ASSESSMENT TECHNIQUE; ATTRIBUTABLE RISKS; COMPARATIVE STUDIES; OUT-OF-FIELD DOSE; RADIATION TREATMENTS; SECOND CANCER; SECOND PRIMARY CANCER; WHOLE-BODY PHANTOMS;

RISK ASSESSMENT;

EID: 77952414078     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3367012     Document Type: Article

References (37)

1. A. Pollack and G. K. Zagars, " Radiotherapy vs. surgery for prostate cancer: An age old question.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 35, 407-409 (1996). 10.1016/0360-3016(96)00142-3 (Pubitemid 26158765)
2. A. L. Potosky, " Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study.," J. Natl. Cancer Inst. JNCIEQ 0027-8874 92, 1582-1592 (2000). 10.1093/jnci/92.19. 1582
3. J. B. Madalinska, " Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer.," J. Clin. Oncol. JCONDN 0732-183X 19, 1619-1628 (2001).
4. P. A. Kupelian, " Comparison of the efficacy of local therapies for localized prostate-specific antigen era: A large single-institution experience with radical prostectomy and external-beam radiotherapy.," J. Clin. Oncol. JCONDN 0732-183X 20, 3376-3385 (2002). 10.1200/JCO.2002.01.150
5. M. J. Zelefsky and S. A. Leibel, " Comparing contemporary surgery to external-beam radiotherapy for clinically localized prostate cancer.," J. Clin. Oncol. JCONDN 0732-183X 203, 3363-3364 (2002).
6. X. Bosch, " Radiotherapy versus surgery for prostate cancer.," Lancet Oncol. LOANBN 1470-2045 6, 263-263 (2005). 10.1016/S1470-2045(05)70150-9 (Pubitemid 40590254)
7. D. J. Brenner, " Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.," Cancer ZZZZZZ 0008-543X 88, 398-406 (2000). 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0. CO;2-V
8. D. J. Brenner, " Induced second cancer after prostate-cancer radiotherapy: No cause for concern?," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 65, 637-639 (2006).
9. D. J. Brenner and E. J. Hall, Making the Radiotherapy Decision (Lowell, Los Angeles, 1996).
10. N. N. Baxter, " Increased risk of rectal cancer after prostate irradiation: A population-based study.," Gastroenterology GASTAB 0016-5085 128, 819-824 (2005). 10.1053/j.gastro.2004.12.038 (Pubitemid 40523534)
11. B. Movsas, " Is there an increased risk of second primaries following prostate irradiation?," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 41, 251-255 (1998). 10.1016/S0360-3016(97)00570-1 (Pubitemid 28243533)
12. T. Pickles and N. Phillips, " The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000.," Radiother. Oncol. RAONDT 0167-8140 65, 145-151 (2002). 10.1016/S0167-8140(02)00307-9 (Pubitemid 35441045)
13. A. I. Neugut, " Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma.," Cancer ZZZZZZ 0008-543X 79, 1600-1604 (1997). 10.1002/(SICI)1097-0142(19970415)79:8<1600::AID- CNCR24>3.0.CO;2-0
14. E. J. Hall and C. S. Wuu, " Radiation-induced second cancers: The impact of 3D-CRT and IMRT.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 56, 83-88 (2003). 10.1016/S0360-3016(03)00073-7 (Pubitemid 36403679)
15. X. G. Xu, B. Bednarz, and H. Paganetti, " A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction.," Phys. Med. Biol. PHMBA7 0031-9155 53, R193-R241 (2008). 10.1088/0031-9155/53/13/R01 (Pubitemid 352020053)
16. M. Tubiana, " Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review.," Radiother. Oncol. RAONDT 0167-8140 91, 4-15 (2009). 10.1016/j.radonc.2008.12.016
17. S. F. Kry, M. Salehpour, D. S. Followill, M. Stovall, D. A. Kuban, R. A. White, and I. I. Rosen, " The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 62, 1195-1203 (2005). 10.1016/j.ijrobp. 2005.03.053
18. U. Schneider, " The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 68, 892-897 (2007). 10.1016/j.ijrobp.2007.02.029
19. J. D. Fontenot, A. K. Lee, and W. D. Newhauser, " Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 74, 616-622 (2009). 10.1016/j.ijrobp.2009.01.001
20. W. S. Kendal, L. Eapen, R. MacRae, S. Malone, and G. Nicholas, " Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 65, 661-668 (2006). 10.1016/j.ijrobp.2005.11.013
21. U. Schneider, " Calculated risk of secondary malignancy from intensity-modulated radiotherapy: In regard to Kry.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 64, 1290-1290 (2006). 10.1016/j.ijrobp. 2005.10.032
22. W. Dorr and T. Herrmann, " Second primary tumors after radiotherapy for malignancies.," Strahlenther. Onkol. STONE4 0179-7158 7, 357-362 (2002).
23. R. M. Howell, " Calculation of effective dose from measurement of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies.," Med. Phys. MPHYA6 0094-2405 33, 360-368 (2006). 10.1118/1.2140119 (Pubitemid 43183978)
24. F. Verellen and F. Vanhavere, " Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region.," Med. Phys. MPHYA6 0094-2405 53, 199-203 (1999).
25. C. Zacharatou Jarlskog and H. Paganetti, " Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 72, 228-235 (2008). 10.1016/j.ijrobp.2008.04.069
26. B. Bednarz and X. G. Xu, " Monte Carlo modeling of a 6 and 18 MV Varian Clinac medical accelerator for in-field and out-of-field dose calculations: Development and validation.," Phys. Med. Biol. PHMBA7 0031-9155 54, N43-N57 (2009). 10.1088/0031-9155/54/4/N01
27. B. Bednarz, C. Hancox, and X. G. Xu, " Calculated organ doses from selected prostate treatment plans using Monte Carlo simulations and an anatomically realistic computational phantom.," Phys. Med. Biol. PHMBA7 0031-9155 54, 5271-5286 (2009). 10.1088/0031-9155/54/17/013
28. BEIR, Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII, Phase 2 (National Academy of Science, Washington, DC, 2006).
29. J. Zhang, Y. H. Na, P. Caracappa, and X. G. Xu, " RPI-AM and RPI-AF, a pair of mesh-based, size-adjustable adult male and female computational phantoms using ICRP-89 parameters and their calculations for organ doses from monoenergetic photon beams.," Phys. Med. Biol. PHMBA7 0031-9155 54, 5885-5908 (2009). 10.1088/0031-9155/54/19/015
30. B. S. Athar and H. Paganetti, " Neutron equivalent doses and associated lifetime cancer incidence risks for head and neck and spinal proton therapy.," Phys. Med. Biol. PHMBA7 0031-9155 54, 4907-4926 (2009). 10.1088/0031-9155/54/16/005
31. R. N. Anderson and P. B. Deturk, " United States life tables 1999.," Natl. Vital Stat. Rep. ZZZZZZ 50, 1-12 (2002).
32. SEER Cancer Statistics Review, 1975-2005 (http://seer.cancer.gov/csr/ 1975, 2005).
33. U. Schneider, " The impact of IMRT and proton radiotherapy on secondary cancer incidence.," Strahlenther. Onkol. STONE4 0179-7158 182, 647-652 (2006). 10.1007/s00066-006-1534-8 (Pubitemid 44657651)
34. ICRP, Recommendations of the International Commission on Radiological Protection, ICRP Publication 60 (Pergamon, Oxford, 1991).
35. S. F. Kry, M. Salehpour, U. Titt, R. A. Allen, M. Stovall, and D. Followill, " Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy.," Radiother. Oncol. RAONDT 0167-8140 91, 132-137 (2009). 10.1016/j.radonc.2008.11. 020
36. ICRP, ICRP Publication 92 (Pergamon, Oxford, 2003).
37. D. J. Brenner and E. J. Hall, " Secondary neutrons in clinical proton radiotherapy: A charged issue.," Radiother. Oncol. RAONDT 0167-8140 86, 165-170 (2008). 10.1016/j.radonc.2007.12.003